Time-restricted eating (TRE) may not add additional benefit in visceral adipose tissue reduction over the Mediterranean diet ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

California gastroenterologist Dr. Saurabh Sethi has called out three popular drinks that increase the risk of Alzheimer’s.

Leading health experts challenge traditional BMI measurements and introduce a comprehensive new approach to diagnosing obesity, potentially affecting millions.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Eating breakfast regularly has been shown to help reduce the risk of developing type 2 diabetes, cardiovascular disease and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Read about the top 15 political, economic, social, environmental, technology and industry trends that will shape 2025 and ...